Display options
Cite
Ngamcherdtrakul W, Morry J, Gu S, et al. Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer. Adv Funct Mater. 2015;25(18):2646-2659doi: 10.1002/adfm.201404629.
Ngamcherdtrakul, W., Morry, J., Gu, S., Castro, D. J., Goodyear, S. M., Sangvanich, T., Reda, M. M., Lee, R., Mihelic, S. A., Beckman, B. L., Hu, Z., Gray, J. W., & Yantasee, W. (2015). Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer. Advanced functional materials, 25(18), 2646-2659. https://doi.org/10.1002/adfm.201404629
Ngamcherdtrakul, Worapol, et al. "Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer." Advanced functional materials vol. 25,18 (2015): 2646-2659. doi: https://doi.org/10.1002/adfm.201404629
Ngamcherdtrakul W, Morry J, Gu S, Castro DJ, Goodyear SM, Sangvanich T, Reda MM, Lee R, Mihelic SA, Beckman BL, Hu Z, Gray JW, Yantasee W. Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer. Adv Funct Mater. 2015 May 13;25(18):2646-2659. doi: 10.1002/adfm.201404629. PMID: 26097445; PMCID: PMC4469082.
Copy Download .nbib Format: NLM
Share it on

Adv Funct Mater. 2015 May 13;25(18):2646-2659. doi: 10.1002/adfm.201404629.

Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.

Advanced functional materials

Worapol Ngamcherdtrakul, Jingga Morry, Shenda Gu, David J Castro, Shaun M Goodyear, Thanapon Sangvanich, Moataz M Reda, Richard Lee, Samuel A Mihelic, Brandon L Beckman, Zhi Hu, Joe W Gray, Wassana Yantasee

Affiliations

  1. Department of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.

PMID: 26097445 PMCID: PMC4469082 DOI: 10.1002/adfm.201404629

[No abstract available.]

Keywords: HER2+ breast cancer; cancer nanomedicine; mesoporous silica nanoparticles; siRNA

References

  1. Mol Ther Nucleic Acids. 2012 Feb 07;1:e8 - PubMed
  2. J Interferon Cytokine Res. 2008 Apr;28(4):221-33 - PubMed
  3. Integr Biol (Camb). 2013 Jan;5(1):66-73 - PubMed
  4. Oncogenesis. 2012 Jul 02;1:e16 - PubMed
  5. Small. 2009 Jan;5(1):57-62 - PubMed
  6. Nature. 2010 Apr 15;464(7291):1067-70 - PubMed
  7. Mol Biosyst. 2012 Apr;8(5):1553-70 - PubMed
  8. Adv Drug Deliv Rev. 2002 Jun 17;54(4):459-76 - PubMed
  9. Nanoscale. 2013 May 21;5(10):4291-301 - PubMed
  10. J Control Release. 2003 Apr 14;89(1):113-25 - PubMed
  11. J Am Chem Soc. 2012 Apr 4;134(13):5722-5 - PubMed
  12. J Gene Med. 2005 Oct;7(10):1287-98 - PubMed
  13. Sci Transl Med. 2012 Apr 18;4(130):130ra48 - PubMed
  14. ISRN Oncol. 2012;2012:428062 - PubMed
  15. Proc Natl Acad Sci U S A. 2012 Feb 21;109 (8):3137-42 - PubMed
  16. Theranostics. 2014 Feb 15;4(5):487-97 - PubMed
  17. Breast Cancer Res. 2011;13(6):R121 - PubMed
  18. Mol Pharm. 2009 May-Jun;6(3):659-68 - PubMed
  19. Nanobiotechnology. 2007 May 1;3(2):89-95 - PubMed
  20. J Control Release. 2002 Aug 21;82(2-3):441-54 - PubMed
  21. Bioconjug Chem. 2006 Sep-Oct;17(5):1209-18 - PubMed
  22. Clin Cancer Res. 2012 Jun 15;18(12):3340-51 - PubMed
  23. Ann Oncol. 2001;12 Suppl 1:S23-8 - PubMed
  24. Science. 2004 Mar 19;303(5665):1818-22 - PubMed
  25. Int J Nanomedicine. 2011;6:1903-12 - PubMed
  26. J Control Release. 2000 Mar 1;65(1-2):271-84 - PubMed
  27. J Phys Chem B. 2013 Sep 12;117(36):10405-13 - PubMed
  28. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  29. J Colloid Interface Sci. 2007 Jun 15;310(2):446-55 - PubMed
  30. Biomaterials. 2007 Jul;28(19):2959-66 - PubMed
  31. Nat Rev Cancer. 2011 Jan;11(1):59-67 - PubMed
  32. J Surg Sci. 2013 Dec;1(1):3-7 - PubMed
  33. Colloids Surf B Biointerfaces. 2000 Oct 1;18(3-4):301-313 - PubMed
  34. Int Immunol. 2005 Jan;17(1):1-14 - PubMed
  35. Macromol Biosci. 2013 Sep;13(9):1163-73 - PubMed
  36. Mol Pharmacol. 2010 Sep;78(3):402-10 - PubMed
  37. ACS Nano. 2011 Apr 26;5(4):2756-69 - PubMed
  38. Biomaterials. 2013 Jan;34(4):1391-401 - PubMed
  39. Nat Rev Drug Discov. 2009 Feb;8(2):129-38 - PubMed
  40. Molecules. 2005 Jan 31;10(1):34-64 - PubMed
  41. Clin Cancer Res. 2004 Nov 1;10 (21):7244-51 - PubMed
  42. Clin Cancer Res. 2007 Aug 15;13(16):4909-19 - PubMed
  43. Cancer Discov. 2013 Apr;3(4):406-17 - PubMed
  44. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301 - PubMed
  45. Traffic. 2009 Jun;10(6):621-8 - PubMed
  46. Sci Transl Med. 2013 Oct 30;5(209):209ra152 - PubMed
  47. Nat Mater. 2013 Nov;12(11):967-77 - PubMed
  48. Nature. 2012 Oct 4;490(7418):61-70 - PubMed
  49. Pharmacotherapy. 2010 Jan;30(1):70-9 - PubMed
  50. Breast Cancer Res. 2006;8(6):215 - PubMed
  51. Biologics. 2009;3:289-301 - PubMed
  52. Adv Mater. 2012 Mar 22;24(12):1504-34 - PubMed
  53. Gene Ther. 2006 Mar;13(6):541-52 - PubMed
  54. Clin Cancer Res. 2013 Apr 15;19(8):2061-70 - PubMed
  55. Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21 - PubMed
  56. Nat Rev Drug Discov. 2002 Sep;1(9):727-30 - PubMed
  57. Theranostics. 2013 Dec 11;4(1):81-9 - PubMed
  58. Cold Spring Harb Perspect Biol. 2010 Jul;2(7):a003327 - PubMed
  59. Int Immunol. 2014 Jan;26(1):35-46 - PubMed
  60. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):904-16 - PubMed
  61. Breast Cancer Res. 2010;12(3):R41 - PubMed
  62. Nat Rev Drug Discov. 2010 Aug;9(8):615-27 - PubMed
  63. Sci Transl Med. 2012 Aug 15;4(147):147ra112 - PubMed
  64. Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54 - PubMed
  65. Int J Nanomedicine. 2011;6:1977-90 - PubMed
  66. Mol Ther. 2011 Mar;19(3):479-89 - PubMed
  67. Toxicol Sci. 2011 Sep;123(1):133-43 - PubMed
  68. Eur J Immunol. 2008 Sep;38(9):2616-25 - PubMed
  69. ACS Nano. 2013 Feb 26;7(2):994-1005 - PubMed

Publication Types

Grant support